Medicare’s New Program Enrolls Over 600,000 for GLP-1 Weight-Loss Drugs

Introduction

Medicare is seeing a surge in enrollment for GLP-1 weight-loss medications, with more than 600,000 beneficiaries opting in during the first two months of a new government initiative.

Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services (CMS), announced that the program limits patient costs to $50 per month, making these previously expensive obesity treatments accessible to seniors.

Impact of the Program

Historically, high costs have made GLP-1 medications like Wegovy and Zepbound out of reach for many Americans, particularly retirees. Prior to this program, patients faced out-of-pocket costs exceeding $1,000 monthly, highlighting the need for affordable options.

Michael Ryan, a finance expert, emphasized the program’s importance, noting that it transforms access from a substantial financial burden into a manageable monthly expense. The quick uptake reflects a significant demand among retirees.

Program Details

Launched on July 1, the Medicare GLP-1 Bridge program is set to run until December 31, 2027. It offers eligible beneficiaries covered GLP-1 medications with a fixed $50 monthly copayment. Covered drugs include Wegovy, Eli Lilly’s Zepbound KwikPen, and Foundayo, an oral GLP-1 option.

The program aims to provide a temporary solution and gauges its impact on health outcomes and Medicare spending. CMS is assessing whether integrating similar coverage into Medicare Part D is feasible.

Eligibility Criteria

Medicare beneficiaries must have Part D prescription coverage and meet specific clinical requirements related to body mass index (BMI) and medical conditions.

Eligibility Criteria:

• BMI of 35 or higher
• BMI of 30 or higher with specific health conditions
• BMI of 27 or higher with cardiovascular disease histories or prediabetes

Some patients might already qualify for GLP-1 coverage through traditional Medicare Part D, particularly those with Type 2 diabetes or chronic health conditions.

Potential Challenges

Kevin Thompson, CEO of 9i Capital Group, cautioned that high participation could strain drug supplies for illnesses originally targeted by these medications. Such disruptions could impact those with chronic conditions.

Future decisions on the program’s continuation will depend on gathered data assessing costs and health outcomes. The termination on December 31, 2027, leaves uncertainties about future cost structures for enrollees.

Thompson noted potential pitfalls related to medication discontinuation, leading to weight rebound or digestive side effects. Considering these drugs’ expanding use, long-term impacts remain uncertain.